Dev Prasad
Stock Analyst at LUCID CAPITAL MARKETS
(3.14)
# 1,140
Out of 5,239 analysts
7
Total ratings
83.33%
Success rate
113.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNRX Quoin Pharmaceuticals | Initiates: Buy | $30 | $6.07 | +394.23% | 1 | May 4, 2026 | |
| ATYR aTyr Pharma | Downgrades: Neutral | $11 → $1 | $0.53 | +88.61% | 1 | Sep 15, 2025 | |
| CUE Cue Biopharma | Initiates: Buy | $120 | $29.26 | +310.12% | 1 | Aug 25, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $5 | $5.18 | -3.47% | 1 | Jun 17, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $24 | $19.94 | +20.36% | 1 | Dec 17, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $6 | $1.61 | +272.67% | 1 | Dec 17, 2024 | |
| CALC CalciMedica | Initiates: Buy | $13 | $0.63 | +1,962.84% | 1 | Dec 17, 2024 |
Quoin Pharmaceuticals
May 4, 2026
Initiates: Buy
Price Target: $30
Current: $6.07
Upside: +394.23%
aTyr Pharma
Sep 15, 2025
Downgrades: Neutral
Price Target: $11 → $1
Current: $0.53
Upside: +88.61%
Cue Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $120
Current: $29.26
Upside: +310.12%
Opus Genetics
Jun 17, 2025
Initiates: Buy
Price Target: $5
Current: $5.18
Upside: -3.47%
Avalo Therapeutics
Dec 17, 2024
Initiates: Buy
Price Target: $24
Current: $19.94
Upside: +20.36%
iBio, Inc.
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $1.61
Upside: +272.67%
CalciMedica
Dec 17, 2024
Initiates: Buy
Price Target: $13
Current: $0.63
Upside: +1,962.84%